Patents by Inventor Yueh-Ming Loo

Yueh-Ming Loo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEIC ACID MOLECULES
    Publication number: 20240277834
    Abstract: The present disclosure relates to a nucleic acid molecule comprising 5?-UTR and/or 3?-UTR sequences that yield high translation levels. Aspects of the disclosure further relate to nucleic acid molecules suitable for use as a vaccine in the treatment and prevention of infectious diseases, including those caused by a coronavirus, compositions comprising said nucleic acid molecules and methods of treating or preventing infectious diseases.
    Type: Application
    Filed: January 19, 2024
    Publication date: August 22, 2024
    Inventors: Albert George THOM, Joseph Richard FRANCICA, Wade Stanton BLAIR, Jason Paul LALIBERTE, Julie Ann DOUTHWAITE, Philip A. NEWTON, Gareth John GRIFFIN, Colin Harold HARDMAN, Yueh-Ming LOO
  • VACCINE
    Publication number: 20240277835
    Abstract: The present disclosure relates to methods of inducing a pan-sarbecoronavirus variant immune response for the treatment and prevention of coronavirus infections.
    Type: Application
    Filed: January 19, 2024
    Publication date: August 22, 2024
    Inventors: Joseph Richard FRANCICA, Wade Stanton BLAIR, Jason Paul LALIBERTE, Yueh-Ming LOO
  • Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
    Patent number: 12023375
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: July 2, 2024
    Assignee: University of Washington
    Inventors: Michael J. Gale, Jr., Gretja Schnell, Yueh-Ming Loo
  • SARS-COV-2 ANTIBODIES AND METHODS OF SELECTING AND USING THE SAME
    Publication number: 20240182548
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.
    Type: Application
    Filed: November 30, 2023
    Publication date: June 6, 2024
    Inventors: Mark ESSER, James STEINHARDT, Patrick MCTAMNEY, II, Yueh-Ming LOO, Reena M. VARKEY, Qun DU, Saravanan RAJAN
  • SARS-COV-2 ANTIBODIES FOR TREATMENT AND PREVENTION OF COVID-19
    Publication number: 20240092875
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of using such antibodies and antigen-binding fragments thereof for the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.
    Type: Application
    Filed: August 9, 2023
    Publication date: March 21, 2024
    Inventors: Robert GASSER, Mark ESSER, Patrick MCTAMNEY, II, Yueh-Ming LOO, Reena M. VARKEY, Qun DU, James STEINHARDT, Saravanan RAJAN
  • SARS-COV-2 PROTEINS, ANTI-SARS-COV-2 ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20230279078
    Abstract: The present disclosure provides SARS-CoV-2 spike proteins and trimers containing such spike proteins. The present disclosure also provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2. The proteins, trimers, and antibodies can be used, for example, to detect anti-SARS-CoV-2 antibodies in sample obtained from a subject.
    Type: Application
    Filed: July 19, 2021
    Publication date: September 7, 2023
    Inventors: GLEN HUGHES, RUTH E. MARCH, MARK ESSER, PATRICK MCTAMNEY II, YUEH-MING LOO, REENA M. VARKEY, QUN DU, JAMES STEINHARDT, SARAVANAN RAJAN
  • Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling
    Publication number: 20220331418
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Application
    Filed: April 4, 2022
    Publication date: October 20, 2022
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo
  • Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
    Patent number: 11324817
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: May 10, 2022
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Michael J. Gale, Jr., Gretja Schnell, Yueh-Ming Loo
  • SARS-COV-2 ANTIBODIES FOR TREATMENT AND PREVENTION OF COVID-19
    Publication number: 20220041694
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of using such antibodies and antigen-binding fragments thereof for the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.
    Type: Application
    Filed: August 9, 2021
    Publication date: February 10, 2022
    Inventors: Robert GASSER, Mark ESSER, Patrick MCTAMNEY, II, Yueh-Ming LOO, Reena M. VARKEY, Qun DU, James STEINHARDT, Saravanan RAJAN
  • SARS-COV-2 ANTIBODIES AND METHODS OF SELECTING AND USING THE SAME
    Publication number: 20210355196
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.
    Type: Application
    Filed: May 17, 2021
    Publication date: November 18, 2021
    Applicant: AstraZeneca UK Limited
    Inventors: Mark ESSER, James STEINHARDT, Patrick MCTAMNEY, II, Yueh-Ming LOO, Reena M. VARKEY, Qun DU, Saravanan RAJAN
  • Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling
    Publication number: 20200276294
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Application
    Filed: October 7, 2019
    Publication date: September 3, 2020
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo
  • Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
    Patent number: 10434164
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: October 8, 2019
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Michael J. Gale, Jr., Gretja Schnell, Yueh-Ming Loo
  • Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling
    Publication number: 20180104325
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Application
    Filed: September 21, 2017
    Publication date: April 19, 2018
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo
  • Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
    Patent number: 9775894
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: October 3, 2017
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Michael J. Gale, Jr., Gretja Schnell, Yueh-Ming Loo
  • Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling
    Publication number: 20150017207
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 15, 2015
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo